Amended Statement of Beneficial Ownership (3/a)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

GMS Tenshi Holdings Pte. Ltd

2. Date of Event Requiring Statement (MM/DD/YYYY) 9/7/2017

3. Issuer Name and Ticker or Trading Symbol

Oncobiologics, Inc. [ONS]

(Last) (First) (Middle)

36 ROBINSON ROAD, #13-01, CITY HOUSE,

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director ___ X ___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

SINGAPORE, U0 068877

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

9/18/2017

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Convertible Preferred Stock ⁽¹⁾	⁽²⁾	⁽³⁾	Common Stock	4932825	$0	D ⁽⁴⁾ ⁽⁵⁾ ⁽⁶⁾

Explanation of Responses:
(1)	This amendment to the Initial Statement of Beneficial Ownership of Securities on Form 3, filed with the Securities and Exchange Commission on September 18, 2017 (the "Original Form 3"), is being filed to add Arun Kumar Pillai ("Kumar") and Ghiath M. Sukhtian ("Sukhtian") as Reporting Persons to the Original Form 3. All of the securities included on this amendment were previously reported on the Original Form 3.
(2)	Each share of Series A Convertible Preferred Stock ("Preferred Stock") is convertible into shares of the Issuer's common stock, par value $0.01 per share, at any time at the election of the holder.
(3)	The Preferred Stock has no expiration date.
(4)	These securities are held of record by GMS Tenshi Holdings Pte. Limited ("GMS Tenshi"). Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Kumar, and GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of GMS Tenshi, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Sukhtian, a natural person, is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma.
(5)	By virtue of the relationships described above in Footnote 3, Kumar and Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Tenshi noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
(6)	The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. GMS Tenshi has designated two representatives, currently Faisal G. Sukhtian (a director of both GMS Pharma and GMS Holdings) and Joe Thomas (a director and executive of a company controlled by Kumar), to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
GMS Tenshi Holdings Pte. Ltd 36 ROBINSON ROAD, #13-01, CITY HOUSE SINGAPORE, U0 068877	X	X
Pillai Arun Kumar #30, "GALAXY", 1ST MAIN, J.P. NAGAR, 3RD PHASE, BANGALORE, K7 560078	X	X
Sukhtian Ghiath M. ZAHRAN ST, 7TH CIRCLE ZAHRAN PLAZA BLDG, 4TH FLR, P.O. BOX 142904, AMMAN, M2 11844	X	X

Signatures
/s/ Faisal G. Sukhtian, By: Faisal G. Sukhtian, Title: Director of GMS Tenshi Holdings Pte. Limited		9/25/2017
^** Signature of Reporting Person		Date
/s/ Arun Kumar Pillai		9/25/2017
^** Signature of Reporting Person		Date
/s/ Ghiath M. Sukhtian		9/25/2017
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.